Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.